Aarti Drugs (NSE:AARTIDRUGS, BOM:524348) has restored production for a "particular product" at its T-150 unit at Tarapur in Maharashtra, India, according to a filing to the stock exchanges on Saturday.
In August, the company received 'Conditional Restart Directions' for manufacturing activity from the Maharashtra Pollution Control Board, after which the company restored the manufacturing process in compliance with the Directorate of Industrial Safety and Health (DISH) recommendations.
The company said the stoppage of manufacturing of the product has no material impact on the financials and operations of the business.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments